Michael Liebowitz is a Psychiatry physician. ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
581 Faunce Corner Rd
Dartmouth, MA 027471242
Telephone
508-207-9800Provider last certified this registry record 27 Apr 2021.
Clinical trials
- Cariprazine Versus Placebo for Social Anxiety Disorder
Sponsor: The Medical Research Network
- Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
Sponsor: Pherin Pharmaceuticals, Inc.
- Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder
Sponsor: The Medical Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alkermes, Inc.Program year20252 payments
- ABBVIE INC.Program year20251 payment
- Teva Pharmaceuticals USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
67.7%Atypical Antipsychotic16.5%Quetiapine Fumarate49%Olanzapine27%Aripiprazole24%Part D≥20 patientsGabapentinoids11.5%Gabapentin100%Part D≥32 patients+ 8 more classes in this area
Cardiovascular
14.3%Central alpha-2 Adrenergic Agonist7.8%Clonidine Hcl100%Part D≥24 patientsStatin3.5%Atorvastatin Calcium100%Part D≥11 patients+ 1 more class in this area
Metabolism & gastrointestinal
10%Opioid Antagonist6.3%Naloxone Hcl100%Part D≥18 patientsProton pump inhibitor3.8%Omeprazole100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”